A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Latest Information Update: 17 Oct 2024
Price :
$35 *
At a glance
- Drugs BAY 1237592 (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms PHOCUS
- Sponsors Pulmovant
- 14 Oct 2024 Status changed from planning to recruiting.
- 11 Sep 2024 New trial record
- 10 Sep 2024 According to a Pulmovant,( Roivant company) media release, the company is expecting to begin the study imminently.